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Abstract 
Class III beta-tubulin is one of the critical proteins associated with microtubule assembly, important to many 
cellular functions including mitochondrial respiration and intracellular trafficking. Widely regarded as a specific 
neuronal marker in developmental neurobiology and stem cell research, it is also highly expressed in a wide 
range of tumors of both neuronal and non-neuronal origin. The expression of class III beta-tubulin is tightly 
controlled at multiple levels with tissue-dependent mechanisms of regulation. For instance, class III beta-tubulin 
expression is under the control of estrogens in breast cancer cells but is influenced by exposure to hypoxia and 
poor-nutrient supply in ovarian cancer. In some but not all cancers, class III beta-tubulin expression is purely a 
prognostic biomarker, predicting poor outcome of patients regardless of chemotherapy treatment. Moreover, the 
expression of class III beta-tubulin does not confer an aggressive phenotype by itself. Instead, class III beta-
tubulin functions like a cytoskeletal gateway, which enhances the incorporation of pro-survival kinases into the 
cytoskeleton and protects them from degradation. The associations of class III beta-tubulin with survival kinase 
PIM-1, RNA-binding protein HuR, microRNAs are examples highlighting the functional complexity of this 
protein. The utility of class III beta-tubulin as a prognostic biomarker can also greatly improve if combined with 
these pro-survival partners. Subsequently, pharmacogenetic approaches, designed to counteract and target these 
pathways and associated-factors concurrently, might lead to better therapies and prognostic tools for class III 
beta-tubulin expressing cancers. 
 
1. Introduction 
Microtubules (MTs) are highly dynamic, 
cytoskeletal structures that are essential to a variety 
of cellular functions, including cell division, 
proliferation, migration, protein trafficking, 
intracellular transport, and maintaining cellular 
polarity (Kreis and Vale, 1993; Katsetos and 
Dráber, 2012). Microtubules are formed by the 
polymerization of the heterodimers: α-tubulin 
subunits and β-tubulin subunits, the isotypes of 
which are encoded by multiple genes (Kreis and 
Vale, 1993; Katsetos and Dráber, 2012). 
Interactions with several microtubule associated 
proteins (MAPs) are crucial to diverse microtubule 
functionality. The phylogenetic analyses from 
vertebrate species suggest α and β isotypes of 
microtubules are highly conserved among species 
but have complex expression pattern, which denote 
cellular and functional specificity and diversity 
(Katsetos et al., 2003).  
There are at least seven mammalian beta-tubulin 
isotypes known to have formed through distinct 
gene products without having gone any splicing 
events (Ludueña, 1998).  
These beta-tubulin subtypes differ from one another 
mainly in a region, which is limited to the last 15 C-
terminal residues.  
Class III beta-tubulin differs from other β-tubulin 
subtypes in its post-translation changes, such as 
differences in phosphorylation and 
polyglutamination in the same terminal residues 
(Orr et al., 2003). Furthermore, TUBB3 gene is the 
most conserved subtype across vertebrate species 
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(Katsetos et al., 2003). In somatic tissues, class III 
beta-tubulin has mostly been used as a biomarker 
for neural stem cells and neuronal differentiation 
during fetal and post-natal development (Caccamo 
et al., 1989; Verdier-Pinard et al., 2009). It is also 
constitutively expressed in the Sertoli cells of the 
testes, transiently expressed in fetal respiratory 
epithelium, and at lower levels at other tissues 
(Verdier-Pinard et al., 2009; Abel et al., 2009). In 
cancers however, class III beta-tubulin is expressed 
in tumors of both neuronal and non-neuronal origin. 
Class III beta-tubulin is by far the most investigated 
microtubule isotype in human cancer. A growing 
body of evidence suggests high expression of class 
III beta-tubulin is associated with poor prognosis 
and aggressiveness of several cancers including 
non-small cell lung cancer (NSCLC), breast, 
ovarian, and gastric cancers (Katsetos and Dráber, 
2012; Katsetos et al., 2003). However, there are 
also reports of expression of class III beta-tubulin 
and good outcome as reported in clear cell ovarian 
cancer and estrogen-receptor negative breast cancer 
(Aoki et al., 2009; Wang et al., 2013). This report 
will try to highlight the function of class III beta-
tubulin and explain the seemingly contradicting 
therapeutic results. 
2. Microtubule targeting agents - 
growing list of agents for cancer 
therapeutics 
The dynamic reorganization of the microtubules 
allows for the formation of mitotic spindle, which is 
crucial for the faithful segregation of chromosomes 
into daughter cells during cell division (Stanton et 
al., 2011).  
Thus, disrupting microtubules to inhibit mitotic cell 
division has become an attractive pharmaceutical 
approach to treat many different cancers. 
Accordingly, Microtubule Targeting Agents 
(MTAs) are some of the most widely used drugs in 
cancer treatment and have met significant clinical 
success (Jordan and Wilson, 2004). MTAs are 
natural, small molecules that interfere with 
microtubule function at low concentrations by 
preventing the formation of normal mitotic spindle 
during cell division, a process that goes awry 
during cancer development (Jordan and Kamath, 
2007). Classically, MTAs being used in cancer 
treatment fall into two kinds of drugs - MT 
stabilizing (taxanes and epothilones) and MT 
destabilizing (Vinca alkaloids) agents. Taxanes - 
paclitaxel docetaxel, abraxane, and cabazitaxel, are 
usually administered in the treatment of a wide 
range of solid cancers, such as breast, ovarian, 
NSCLC, and cancers of the head and the neck. 
Vinca alkaloids, such as vinorelbine, vinflunine and 
vinblastine, are usually used in the treatment of 
hematological malignancies like the lymphoma and 
leukemia (Jordan and Wilson, 2004; Morris and 
Fornier, 2008). Both classes of drugs target specific 
binding sites of beta-tubulin, which disrupt the 
microtubules, inhibiting its assembly or 
disassembly, leading to cell death mostly by 
apoptosis (Morris and Fornier, 2008). However, the 
exact mechanism by which each drug works to 
inhibit microtubules is still speculative and not fully 
explained. Taxanes are regularly administered as 
part of adjuvant therapy in patients with breast, 
ovarian, and non-small cell lung cancer, and recent 
indications suggest that it can further improve 
prognosis and therapy through combination with 
biologic agents (Dumontet and Jordan, 2010; Karki 
et al., 2014). 
The clinical success of taxanes led to development 
of drugs like epothilones, which are macrolide 
antibiotics and can enhance microtubule 
polymerization and structurally more suitable to 
synthetic modifications (Morris and Fornier, 2008; 
Dumontet and Jordan, 2010). Similar to taxanes 
that bind to beta-tubulin, epothilones exert similarly 
and are thought to compete with taxane binding 
sites. More importantly, early trials of epothilones 
seem to indicate that they have better efficacy in 
patients resistant to taxane-including regimen 
(Cheng et al., 2008; Goodin et al., 2004). Some of 
the modified versions of epothilones include 
patupilone, a naturally occurring epothilone, which 
was found to be 20 times more potent than 
paclitaxel in taxane-resistant cell lines. Ixabepilone, 
a semisynthetic version, has also shown to be 
effective in resistant cell lines. Yet, many 
promising agents that interfere with microtubules 
like epothilone B and D analogues, colchicines, and 
laulimalide binding agents are also currently at 
different stages of development (Morris and 
Fornier, 2008; Dumontet and Jordan, 2010). 
3. Mechanism of drug resistance 
- the role of beta III tubulin 
Efficacy of taxanes and other MTAs is limiting due 
to the development of acquired and intrinsic 
resistance of tumor cells to the drugs, as well as 
increased hypersensitivity and neurological 
toxicities. The mechanistic details of such chemo-
resistance are entirely not clear at present. 
However, earlier studies in the 90s on class III beta-
tubulin suggested that this protein mediated 
chemoresistance in response to taxanes and widely 
regarded to be predictive biomarker to taxane-based 
therapies (Derry et al., 1997). Owing to different 
mechanisms of action, this classical theory entailed 
class III beta-tubulin to be predictive of taxane 
based chemotherapy but not of Vinca alkoloids. 
Initial studies on this protein supported this theory, 
where high expression of class III beta-tubulin was 
associated with chemo-resistance in taxane-based 
therapies in different cell-based models.  
This positive correlation of chemo-resistance  
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association was also seen by our group when we 
investigated class III beta-tubulin in the context of 
using paclitaxel in ovarian cancer (Kavallaris et al., 
1997; Mozzetti et al., 2005). More recent data on 
class III beta-tubulin and various MTA agents have 
been rather conflicting. In one of the studies, class 
III beta-tubulin gene silencing desensitized effects 
of both taxanes as well as other drugs, in particular 
cisplatin. In another study, epothilones were found 
to be extremely active in ovarian cancer cell models 
and other gynecological cancers but not for lung 
cancer, even when both sets of cancers exhibited 
high class III beta-tubulin content (Gan et al., 2007; 
Mozzetti et al., 2008; Carrara et al., 2012). To 
further gain insight into this contradiction, our 
group recently did a comprehensive review of 59 
translational studies assessing class III beta-tubulin 
in many different types of cancers. Not 
surprisingly, our analysis refuted the notion that 
class III beta-tubulin is predictive of taxane-based 
chemotherapy (Karki et al., 2013). In those studies 
that claimed class III beta-tubulin to be predictive 
of response to MTA-including chemotherapy, either 
the sample size was small or analyses were not 
stringent. Instead, our analysis of the studies show 
that class III beta-tubulin is a pure prognostic 
biomarker in some solid malignancies, regardless of 
the choice of chemotherapies employed (Karki et 
al., 2013). In order to understand the basis of the 
prognostic capability of class III beta-tubulin, it is 
necessary to understand the mechanisms regulating 
its expression and the varied functions this protein 
may have in the context of different cells and 
tissues (Karki et al., 2013). 
4. Regulation and expression of 
class III beta-tubulin - hormones 
and gender 
In cases of ovarian and breast cancers, hormones 
may play a significant role in the expression and 
regulation of class III beta-tubulin. In breast cancer, 
class III beta-tubulin expression is under the control 
of estrogens. This was demonstrated in a study 
where estradiol exposure to MCF-7 breast cancer 
cell line, positive for estrogen receptor (ER), 
upregulated the TUBB3 mRNA and class III beta-
tubulin protein. However, in cells negative for ER 
such as MDA-MB-231, no such induction was 
observed (Saussede-Aim et al., 2009). In this 
context of ER positive cells, expression of class III 
beta-tubulin cannot confer an aggressive phenotype 
and be linked to resistance of the drug. Instead, 
these ER positive patients with high class III beta-
tubulin expression have better outcome because 
they are sensitive to aromatase inhibitors and other 
anti-hormonal therapies. This was further 
confirmed in this study using ER modulators: 
tamoxifen - a selective ER modulator and 
fulvestrant - a pure antagonist of ER. These 
hormonal modulators were able to inhibit class III 
beta-tubulin mRNA induction suggesting class III 
beta-tubulin expression is mediated through ER 
dependent pathway (Saussede-Aim et al., 2009). 
The evaluation of class III beta-tubulin to predict 
responses and outcome in triple-negative breast 
cancer would be interesting as this breast cancer is 
devoid of effect by ER and other hormones. A 
recent study in Lancet has demonstrated that 
exposure to high levels of oestradiol and 
progesterone found in breast and ovarian cancer 
patients are linked to BRCA1/BRCA2 mutations 
(Widschwendter et al., 2013). In a recent translation 
study of ER negative breast cancer, class III beta-
tubulin was found to correlate with good 
pathogenic response to chemotherapy, suggesting 
the protein maybe identified differently in specific 
subsets of breast cancer (Wang et al., 2013). It is 
unclear if there is any relationship between 
BRCA1/BRCA2 mutations, chemotherapy 
sensitivity, and class III beta-tubulin expression. 
Hormones and gender can also play a role in 
expression of class III beta-tubulin in male cancers. 
In a panel of 23 colorectal cancer cell lines, the 
expression of class III beta-tubulin is increased in 
response to androgens only in males. This basal 
activation of class III beta-tubulin seems associated 
with poor clinical outcome in male colorectal 
cancer patients (Mariani et al., 2012). It was further 
found that CYP17A1, a critical enzyme regulating 
androgen levels, have a specific allele (GG 
phenotype) that confers colorectal patients with 
high level of androgens (Mariani et al., 2012). In 
prostate cancer, there is also an aspect of class III 
beta-tubulin regulation by androgen levels. In one 
study, class III beta-tubulin increased signficantly 
in castration-resistant prostate cancer (CRPC) 
patients after treatment with anti-androgen therapy. 
This is probably due to loss of regulation by 
androgen receptor or CRPC association with 
hypoxic conditions (Forde et al., 2012). 
5. Regulation of beta III tubulin - 
exposure to microenvironment 
and survival pathway 
In many cancers, class III beta-tubulin is a part of 
an adaptive function circuit, which allows cancer 
cells thrive in microenvironment featured with poor 
oxygen and low nutrient supply. Our previous work 
has demonstrated that hypoxia is able to induce 
TUBB3 gene expression through HIF1 binding to 
its 3' region (Raspaglio et al., 2008). In ovarian 
cancer the regulation and expression of class III 
beta-tubulin is more complex and involves the role 
of additional transcription factors, RNA-binding 
proteins such as HuR, microRNAs, and components 
of the survival pathway involved in the adaptation 
to hypoxia. In hypoxic and hypoglycemic 
conditions, prevalent in many advanced cancers 
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including ovarian cancer, RNA binding protein like 
HuR facilitates class III beta-tubulin translation to 
counteract glucose shortage (Raspaglio et al., 
2010). HuR expression is nuclear in normal tissues 
but is found to be cytoplasmic in advanced cancers 
exposed to hypoxia. Cytoplasmic HuR and high 
class III beta-tubulin in ovarian cancer patients are 
indicators of exposure to hypoxia and are linked to 
poor outcome (Raspaglio et al., 2010). A more 
recent work from our group and others have further 
elucidated a combined regulatory mechanism that 
drives class III beta-tubulin expression through 
HuR and miR-200C in ovarian cancer (Prislei et al., 
2013). When HuR is nuclear, a condition typical of 
low stage ovarian cancer, high expression of miR-
200C inhibits TUBB3 expression and results in 
good prognosis. On the other hand, when mir-200C 
is associated to cytoplasmic HuR, the conversion of 
TUBB3 mRNA into beta III tubulin is enhanced, 
resulting in poor outcome of patients (Prislei et al., 
2013). This report demonstrates that the same 
microRNA can exert different cellular functions for 
class III beta-tubulin based on location-specific 
interaction with the RNA-binding protein HuR. 
In ovarian cancer, class III beta-tubulin function is 
linked to the adaptation to hypoxia and poor 
nutrient supply by incorporating pro-survival 
kinases like PIM1 into the cytoskeleton. The 
preferential incorporation of PIM1 into 
microtubules facilitates the cytoskeletal increase of 
the GBP1 GTPase. GBP1 incorporation stabilizes 
binding of the PIM1 kinase into microtubules and 
protects PIM1 from rapid degradation. This 
mechanism is not specific only for PIM1 but it is 
shared by additional kinases such as NEK6, AXL, 
and others (De Donato et al., 2012). As an ensuing 
mechanism, signaling of these pro-survival 
pathways is prolonged, thus enabling cancer cells to 
thrive in hypoxic conditions. Such analogous 
adaptation of cancer cells in harsh 
microenvironment is seen in many cancers, but the 
role of cytoskeleton in the process is only beginning 
to emerge with recent data from class III beta-
tubulin expression. In some ovarian cancer cells, 
regulation of class III beta-tubulin is under the 
control of a transcription factor, Gli1, one of the 
drivers of epithelial-to-mesenchymal transition 
program and also a hallmark of metastatic potential 
of solid tumors. In this study, Gli1 was able to 
increase class III beta-tubulin expression under 
hypoxic conditions conferring a more invasive 




6. Utility of combined biomarkers 
with beta III tubulin to increase 
prognostics 
From both our recent review of translational studies 
of cancers and previous studies on class III beta-
tubulin, it is clear that the utility of class III beta-
tubulin as a biomarker increases significantly when 
used in combination with additional biomarkers, 
proteins, or other discrete factors in different 
cancers. In fact, it is important to stress the concept 
that class III beta-tubulin does not mediate the 
resistant phenotype alone but only in a multi-
molecular concerted pathway. Therefore, it is not 
surprising that this protein, when taken as a single 
agent, can even be a hallmark of good outcome, as 
seen in estrogen positive breast cancer. In a study 
conducted in gastric cancer, the combination of 
thymidine phosphorylase (TP)-positive and class III 
beta-tubulin negative tumors gave a stronger 
predictive power than TP negative and class III 
beta-tubulin positive tumors alone. Both overall 
survival (OS) and progression free survival (PFS) 
reached significance when surviving class III beta-
tubulin was analyzed in combination (Gao et al., 
2011). In another study in gastric cancer, 
inactivation of Brca1 and low class III beta-tubulin 
provide a better utility in predicting responses to 
cytotoxic therapy, regardless of taxane-containing 
or taxane-free drug combinations (Moiseyenko et 
al., 2013). In breast cancer, the double-negative 
expression of class III beta-tubulin and survivin 
responded significantly better to docetaxel and had 
longer PFS (p<0.05) when compared with double-
positive patients (Yuan et al., 2012). In another 
clinical set of breast cancer, the class III beta-
tubulin negative tumors when combined with the 
BCL-2 and ERCC1 proteins increased predictive 
potential in response to CP (carboplatin/paclitaxel) 
therapy (Chen et al., 2012). Since BCL-2 and 
Survivin are both important in the pathway that 
regulates apoptosis; they could possibly impact 
sensitivity to chemotherapy. In ovarian cancer, high 
expression of both class III beta-tubulin and PIM1 
combination has a synergistically higher prognostic 
potential (De Donato et al., 2012). In thymic 
epithelial cancer patients, ERCC1, BRCA1, and 
class III beta-tubulin combination strongly correlate 
with one another and can be used to improve 
accuracy of prognostic and predictive tests against 
chemotherapeutic regimens (Kaira et al., 2011). In 
lung cancer, several studies support the notion of 
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completely resected patients with NSCLC, double 
negative patients with class III beta-tubulin and  
ERCC1 had even more significant improved 
outcome (p=0.023) than when they were used 
individually (Okuda et al., 2008). In patients 
relapsed and treated with platinum/taxane, double 
negative ERCC1 and class III beta-tubulin tumors 
predicted OS significantly. The prediction was not 
significant when class III beta-tubulin was used 
alone (p=0.015 vs. 0.087) (Azuma et al., 2009). 
7. Therapeutic approaches with 
class III beta-tubulin 
Microtubules enriched of class III beta-tubulin are 
featured by increased sensitivity to epothilones, 
particularly to epothilone B. The configuration of 
the pocket binding epothilone B (patupilone) in 
class III beta-tubulin differs from the one present in 
class I beta-tubulin, the most abundantly expressed 
beta-tubulin (Magnani et al., 2006; Ferlini et al., 
2005). Therefore, cells with high expression of 
class III beta-tubulin appears more sensitive to 
patupilone (Mozzetti et al., 2008). This property 
explains the increased effects of epothilones noticed 
in a large number of clinical trials conducted in 
patients relapsing after multiple lines of 
chemotherapy (Ferrandina et al., 2012). Therefore, 
it seems rather attractive to use class III beta-
tubulin as a potential biomarker for selection of 
patients eligible for treatment with epothilones. In 
this regard, such approach necessitates development 
of an integrated biomarker as mentioned above, to 
ensure active status of class III beta-tubulin 
function. 
Based on mechanism of regulation and interaction 
with its functional partners in the tumor 
microenvironment, class III beta-tubulin can be also 
exploited to develop cancer therapeutics. The rapid 
evolution of technologies is providing incredible 
and unprecedented amount of information about 
various forms of cancers. It is becoming feasible to 
dissect functional pathways in cancer cells that are 
responsible for biologic features, in particular, the 
mechanisms leading to resistance of cancer cells to 
cell death programs and ability to resist to radio- 
and chemotherapy. Disruption of such pathways, in 
a "targeted" fashion, should represent the next 
frontier in the development of innovative targeted 
anticancer drugs. In this context, the screening of 
new molecules to directly inhibit class III beta-
tubulin could be challenging because of limitations 
of current technology to synthesize active version 
of the protein. In fact, the functional active tubulin 
not only requires dimerization but also 
posttranslational changes and incorporation into 
microtubules. On the other hand, downstream 
effectors of class III beta-tubulin do not have such 
limitations. The proteins, GBP1 and PIM1, for 
example, can be expressed as recombinant active 
proteins. Their protein-protein interactions may be 
useful to identify new scaffolds to generate novel 
therapeutics that are active in drug-resistant cells. 
Therefore, such an inhibitor of the GBP1:PIM1 
interaction might be useful in those patients, who 
exhibit high level of class III beta-tubulin and 
consequently, have a poor response to 
chemotherapy. As opposed to the currently 
available targeted agents capable of inhibiting one 
kinase family, this new agent is expected to inhibit 
the incorporation of a wide number of kinases into 
the cytoskeleton. Such an effect will have a broader 
but telling impact on the resistant cancer phenotype 
than that achieved by inhibiting a single kinase 
family. 
8. Summary and conclusion 
Class III beta-tubulin will continue to be at the 
forefront of cancer therapeutics, owing to its 
expression in the majority of solid tumors and its 
prognostic potential.  
The field is shifting away from the hypothesis 
linking class III beta-tubulin directly to resistance 
to MTAs based on a single protein mechanism.  
The better comprehension of the mechanisms 
underlying class III beta-tubulin function is 
improving its potential use as a prognostic 
biomarker and as a potential factor to select 
alternative treatments for those patients, where class 
III beta-tubulin pathway confers an aggressive 
phenotype.  
Its role in the functional gateway of cytoskeletal 
drug resistance suggests that inhibition of this 
protein by novel targeted agents will be useful in 
the treatment of diseases, which are currently 
refractory to standard treatments. For all these 
reasons, we expect class III beta-tubulin will 
continue to be actively pursued as a source of new 
diagnostics and therapeutics for aggressive cancers. 
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